Abbvie Inc. · NYSE:ABBV
Abbvie — Merger or Acquisition (December 2023)
14 slides from Abbvie's merger presentation, Dec 6, 2023
Slide 1: Acquisition of Cerevel
Acquisition of Cerevel December 6, 2023 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation, including those relating to the proposed acquisition of Cerevel Therapeutics Holding, Inc. by AbbVie Inc. are, or may be considered, forward- looking statements for purposes of the Private Securities
Slide 3: Strong Strategic Fit for AbbVie
Strong Strategic Fit for AbbVie A unique opportunity to acquire a pipeline of potentially best-in-class assets focused on treating neurological and psychiatric diseases Leverages AbbVie’s commercial capabilities, international infrastructure, and regulatory and clinical expertise to maximize Cerevel
Slide 4: AbbVie Neuro-Psychiatry
AbbVie Neuro-Psychiatry Developing Innovative Therapies for Mood, Thought and Anxiety Disorders Psychiatry Represents a Large AbbVie Aspires to be a Leader in Mood, Thought, and and Underserved Opportunity Anxiety Disorders with High Unmet Need Most prevalent psychiatric conditions in the G7 • Schiz
Slide 5: Cerevel Overview
Cerevel Overview Clinical-Stage Biotechnology Company Focused on the Discovery and Development of Differentiated Therapies for Neuroscience Diseases Selectively Targeting the Receptor Subtype Related to Disease Physiology Differentiated Approach to Treating Neurological Diseases M4 GABAA • Schizophr
Slide 6: Cerevel Pipeline
Cerevel Pipeline IND Phase 1 Phase 2 Phase 3 Tavapadon (D1/D5 Partial Agonist) Parkinson’s Disease Emraclidine (M4 PAM) Schizophrenia Emraclidine (M4 PAM) Alzheimer’s Disease Psychosis Darigabat (GABAA PAM) Epilepsy Darigabat (GABAA PAM) Panic Disorder CVL-871 (D1/D5 Partial Agonist) Dementia-Relate
Slide 7: Emraclidine
Emraclidine Selectively targeting the M4 muscarinic receptor to more effectively treat psychosis related symptoms and improve tolerability Emraclidine is a positive allosteric modulator of the muscarinic M4 receptor (M4 PAM), a new mechanistic class that has the potential to provide significant effi
Slide 8: Emraclidine Has the Potential to Transform Schizophrenia Treatment Landscape
Emraclidine Has the Potential to Transform Schizophrenia Treatment Landscape Potential for Differentiated Side Effect Profile Potential for Best-in-Class Efficacy • Targeting the muscarinic receptor rather than dopamine or • M4-selective PAM has the potential to be effective in the serotonin recepto
Slide 9: CVL-354
CVL-354 Potential Best-in-Class Kappa Opioid Receptor (KOR) Antagonist KOR antagonism is a clinically validated mechanism of action in major depressive disorder KOR antagonists have the potential to provide clinically meaningful improvements in safety and tolerability compared to existing treatments
Slide 10: Multiple Additional High-Potential Pipeline Assets
Multiple Additional High-Potential Pipeline Assets TAVAPADON DARIGABAT CVL-871 Partial agonist selectively targeting the Alpha 2/3/5 selective GABAA Selective partial agonist of the dopamine dopamine D1/D5 receptor receptor PAM D1/D5 receptor subtypes designed to achieve a modest level of partial Po
Slide 11: Creating a More Robust Neuroscience Pipeline
Creating a More Robust Neuroscience Pipeline Phase 3 / Under Regulatory Phase 1 Phase 2 Registrational Review ABBV-CLS-7262 (elF2B Activator) ABBV-916 (A-beta Antibody) Botox (SNARE) Episodic Migraine ABBV-951 (Dopamine Receptor) Vanishing White Matter Disease Alzheimer’s Disease Progression Prevent
Slide 12: Transaction and Financial Overview
Transaction and Financial Overview • AbbVie has agreed to acquire all outstanding shares of Cerevel for a purchase price of $45.00 per share in all-cash transaction PURCHASE • Premium of approximately 73% to the unaffected closing share price on December 1, 2023 PRICE • Purchase price of $8.7B; Impl
Slide 13: Key Takeaways
Key Takeaways A strong strategic fit for AbbVie that represents a unique opportunity to acquire a pipeline of potentially best-in-class assets focused on treating neurological and psychiatric diseases • Provides AbbVie with promising discovery programs and clinical-stage assets that are highly compl
Slide 14: Oovobvie
Oovobvie